International Journal of Clinical Research

Objective: To explore the application value of tegritol in acute ST-segment elevation myocardial infarction. Methods: 45 patients with acute ST-segment elevation myocardial infarction who need to be treated from January 2020 to November 2022 were selected as the observation group, and they were treated with tegrel, and another 45 patients with acute ST-segment elevation myocardial infarction who visited our hospital at the same time were selected as the control group, and they were treated with clopidogrel. Results: ① Before treatment, there was no statistically significant difference between the observation group and the control group in hs-CRP and cTnI. After treatment, the levels of hs-CRP and cTnI in the observation group were significantly improved, P<0.05; ② The respiratory rate, heart rate, blood oxygen saturation, systolic blood pressure and diastolic blood pressure in the observation group and the control group were compared before treatment (P>0.05); The vital signs of the observation group and the control group were compared after treatment (P<0.05). Conclusion: In patients with acute ST-segment elevation myocardial infarction, the treatment effect can be improved and the incidence of cardiovascular adverse events can be reduced.

Tegrillo; Acute ST segment elevation myocardial infarction; Application value